

American Society of Plastic Surgeons Member Post-Operative Opioid Prescribing Patterns

Radbeh Torabi, MD*
 Lynn Bourn, BSN†
 Gerhard S. Munding, MD*
 Fouad Saeg‡
 Charles Patterson, MD*
 Alejandro Gimenez†
 Ian Wisecarver†
 Hugo St. Hilaire, MD, DDS,
 FACS*
 Mark Stalder, MD*
 Oren Tessler, MD, MBA§

Introduction: Despite the widespread use of opioids in pain management, there are currently no evidence-based guidelines for the treatment of postoperative pain with opioids. Although other surgical specialties have begun researching their pain prescribing patterns, there has yet to be an investigation to unravel opioid prescribing patterns among plastic surgeons.

Methods: Survey Monkey was used to sample the American Society of Plastic Surgeons (ASPS) members regarding their opioid prescribing practice patterns. The survey was sent randomly to 50% of ASPS members. Respondents were randomized to 1 of 3 different common elective procedures in plastic surgery: breast augmentation, breast reduction, and abdominoplasty.

Results: Of the 5,770 overall active ASPS members, 298 responses (12% response rate) were received with the following procedure randomization results: 106 for breast augmentation, 99 for breast reduction, and 95 for abdominoplasty. Overall, 80% (N = 240) of respondents used nonnarcotic adjuncts to manage postoperative pain, with 75.4% (N = 181) using nonnarcotics adjuncts >75% of the time. The most commonly prescribed narcotics were Hydrocodone with Acetaminophen (Lortab, Norco) and Oxycodone with Acetaminophen (Percocet, Oxycocet) at 42.5% (N = 116) and 38.1% (N = 104), respectively. The most common dosage was 5 mg (80.4%; N = 176), with 48.9% (N = 107) mostly dispensing 20–30 tablets, and the majority did not give refills (94.5%; N = 207).

Conclusions: Overall, plastic surgeons seem to be in compliance with proposed American College of Surgeon's opioid prescription guidelines. However, there remains a lack of evidence regarding appropriate opioid prescribing patterns for plastic surgeons. (*Plast Reconstr Surg Glob Open* 2019;7:e2125; doi: 10.1097/GOX.0000000000002125; Published online 13 March 2019.)

INTRODUCTION

Despite the widespread use of opioids in pain management, there are currently no evidence-based guidelines for the treatment of postoperative pain with opioids. According to data collected by the American College of Surgeons (ACS) National Surgical Quality Improvement Program, 9 out of 10 surgical patients received an opioid prescription at discharge.¹ Meanwhile, 80% of patients

complain of undertreated postoperative pain, with 75% describing the pain as moderate, severe, or extreme.² These data highlight the inadequacy of employing a “one-size-fits-all,” opioid-based protocol which often leads to significant variation in the type of narcotic, the number of pills dispensed, and the dosage prescribed.³ In 2014, Current Concepts in Pain Management in Plastic Surgery combined a multidisciplinary approach from multiple articles in regards to treating pain. The supplement focused on a multimodal analgesic approach with opioids as an adjunctive role as opposed to the primary treatment modality.⁴

Alarming, the number of opioid prescriptions has increased by 400% from 1999 to 2014.⁵ However, the amount of pain reported by American patients has remained constant.^{6,7} The opioid epidemic is more prevalent today than ever before, with over 5 million Americans abusing opioids, resulting in >33,000 deaths annually and an economic burden of \$78.5 billion

From the *Department of Surgery, Section of Plastic & Reconstructive Surgery, Louisiana State University Health Sciences Center, New Orleans, La.; †School of Medicine, Louisiana State University Health Sciences Center, New Orleans, La.; ‡School of Medicine, Tulane University, New Orleans, La.; and §Elite Plastic Surgery, Phoenix, Ariz.

Received for publication September 13, 2018; accepted December 5, 2018.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI: 10.1097/GOX.0000000000002125

Disclosure: The authors have no financial interest to declare in relation to the content of this article.

per year.^{8–10} Over 70% of opioid abusers receive drugs through inappropriately obtained prescriptions, with more than half obtaining drugs from a family member or friend with excess pills.^{11,12} Despite their popularity in the treatment of postsurgical pain, opioid prescriptions written by surgeons often go unused. Surgeons prescribe 2–5 times more opioids than consumed, and 83% of patients claim to finish only half of the prescription.^{13,14} This phenomenon directly contributes to our nation's opioid epidemic and puts the patient, their family, and the community at risk.¹⁵

Although other surgical specialties have begun researching their pain prescribing patterns, there has yet to be an investigation to unravel the patterns among plastic surgeons. The purpose of this study is to determine pain management regimens used by board-certified plastic surgeons in the United States and how this correlates to their practice or demographic characteristics, including trends in narcotic prescriptions and pain management education.

METHODS

Survey Monkey (SurveyMonkey Inc., San Mateo, Calif.; website: www.surveymonkey.com) was used to sample the American Society of Plastic Surgeons (ASPS) members regarding their opioid prescribing practice patterns. The survey was sent randomly to 50% of ASPS members. The survey contained 67 questions, and respondents were randomized to 1 of 3 different invasive procedures that are some of the most common in plastic surgery based on ASPS statistics: breast augmentation, breast reduction, and abdominoplasty.¹⁶ Page randomization and branching logic was used so that when each respondent started a survey, they were randomized to 1 of the 3 procedures, to answer specific procedure questions, then all were redirected to the same questions directed at their overall practice. Questions for each procedure ascertained the frequency of use of nonnarcotic adjuncts and the narcotic prescribing patterns. Nonnarcotic adjuncts being described as either liposomal bupivacaine (Exparel; Pacira, Parsippany, N.J.), other long-acting anesthetic agent (bupivacaine, levobupivacaine, ropivacaine), intravenous acetaminophen (Ofirmev; Mallinckrodt Pharmaceuticals, Staines-upon-Thames, United Kingdom), or Ketorolac (Toradol; Hoffmann-La Roche, Switzerland). Afterwards, each respondent subsequently answered questions in the following categories: prescribing narcotic patterns, changes in prescribing patterns in the last 5–10 years, practice characteristics, institutional characteristics, narcotic training/education, and narcotic patient education. Survey questions are presented in Table 1. Data were analyzed for comparison between procedures and correlation between physician or institutional characteristics and prescribing patterns by means of chi-square and Fisher exact tests (StataCorp, 2015, Stata Statistical Software: Release 14; StataCorp LP, College Station, Tex.). Multivariate analysis was not

performed due to insufficient univariate significance of predictor variables.

RESULTS

Demographics and Physician/Practice Characteristics

Of the randomly surveyed 2,885 ASPS members (50% of 5,770 total members), 298 responses were received (12% response rate). Upon comparing the respondent sample with self-reported demographic information for all ASPS members (Fig. 1), the only significant differences were that there was a larger number of respondents who were males (N = 232, 78%; $P = 0.0067$) who were in solo practice settings (N = 151, 57%; $P = 0.0144$) and who performed varying combinations of cosmetic and reconstructive procedures in their practice (74%, N = 206; $P = 0.0195$). The following are demographic results from the survey. In terms of practice setting and its effects on prescription patterns, the majority of plastic surgeons (66.1%; N = 187) had a private practice setting in an urban (61.8%; N = 175) location. The surgeons (48.1% only; N = 136) accepted self-pay, whereas 40.3% (N = 114) accepted most forms of payment (self-pay, private insurance, Medicare, and Medicaid). There was no statistical difference between practice settings ($P = 0.467$) or location ($P = 0.836$) upon comparison to narcotic prescriptions for postoperative pain management. Self-pay-only plastic surgeons had a 100% rate of narcotic use as part of their discharge packets. This was significantly higher than those who accept all forms of payment ($P = 0.035$). However, self-pay plastic surgeons were no different in the amount of nonnarcotic prescriptions used ($P = 0.100$) or narcotic prescriptions used ($P = 0.161$) to manage postoperative pain.

Prescribing Patterns by Procedure: Breast Augmentation, Breast Reduction, Abdominoplasty

Survey respondents were randomized as follows: 106 for breast augmentation, 99 for breast reduction, and 95 for abdominoplasty. Overall, 80% (N = 240) of respondents used nonnarcotic adjuncts to manage postoperative pain; with 75.4% (N = 181) using nonnarcotics adjuncts >75% of the time. The respondents (92.6%; N = 296) prescribed a narcotic for postoperative pain, with the prescription being a standard part (96.4%; N = 277) of their perioperative discharge package/care plan for the procedure. The most commonly prescribed narcotics were Hydrocodone with Acetaminophen (UCB Pharma, Brussels, Belgium) and Oxycodone with Acetaminophen (Endo Pharmaceuticals, Dublin, Ireland) at 42.5% (N = 116) and 38.1% (N = 104), respectively. Out of these 220 plastic surgeons, the most common dosage was 5 mg (80.4%; N = 176), with 48.9% (N = 107) mostly dispensing 20–30 tablets and the majority did not give refills (94.5%; N = 207). See Figures 2–5 for full graphical comparison. Upon statistical comparison between procedures, there was no significant variation in the use of nonnarcotic adjuncts ($P = 0.646$) or narcotic prescription use ($P = 0.463$).

Table 1. List of Survey Questions with Answer Choices**Questions Specific to Each Procedure**

1. Do you use any of the following nonnarcotic adjuncts to manage (*breast augmentation OR breast reduction OR abdominoplasty*) patient postoperative pain? <YES/NO>
Exparel (liposomal bupivacaine), other long-acting anesthetic agent (bupivacaine, levobupivacaine, ropivacaine), Ofirmev (intravenous acetaminophen), Toradol (Ketorolac)
2. On average, how often do you use a nonnarcotic adjunct to manage (*breast augmentation OR breast reduction OR abdominoplasty*) patient postoperative pain?
<25%, 25%–50%, 51%–75%, >75%
3. Do you prescribe a narcotic for patients undergoing a (*breast augmentation OR breast reduction OR abdominoplasty*)? <YES/NO>
4. Is the narcotic prescription a standard part of your perioperative discharge package/care plan for (*breast augmentation OR breast reduction OR abdominoplasty*) patients? <YES/NO>
5. Which of the following narcotics do you prescribe most often for a (*breast augmentation OR breast reduction OR abdominoplasty*)?
Dosage (mg/mg), Dispense (No.), Refills (No.)
Hydrocodone with Acetaminophen
Hydrocodone with Ibuprofen
Hydrocodone with Aspirin
Oxycodone (Roxicodone)
Oxycodone with Acetaminophen
Oxycodone with Ibuprofen (Combunox = 5 mg/400 mg)
Oxycodone with Aspirin
Tramadol
Codeine with Acetaminophen
Codeine with Aspirin (Co-Codaprin = 8 mg/400 mg)
Codeine with Ibuprofen (Nurofen = 12.8 mg/200 mg)
If the narcotic you prescribe is different than the choices given please specify:
Drug, Dosage (mg or mg/mg), Dispense (No.), Refills (No.)

General questions (not specific to one procedure)

6. How has your narcotic prescribing frequency changed in the last 5–10 y?
Increased, Unchanged, Decreased
7. In the last 5 years, have you noticed a change in the frequency of narcotic prescription refill requests by patients during the postoperative period?
Major increase, Minor increase, No change, Minor decrease, Major decrease
8. On average, how many of your postoperative patients display drug seeking behavior of any kind to receive added narcotics?
<25%, 25%–50%, 51%–75%, >75%
9. In the last 5 y, have you noticed a change in the frequency of this drug seeking behavior?
Major increase, Minor increase, No change, Minor decrease, Major decrease
10. On average, how many of your postoperative patients display aggressive behavior to receive additional narcotics?
<25%, 25%–50%, 51%–75%, >75%
11. In the last 5 y, have you noticed a change in the frequency of this aggressive behavior for narcotics?
Major increase, Minor increase, No change, Minor decrease, Major decrease
12. At any point have you been threatened by a patient, who was requesting additional narcotics, to the point that you felt unsafe? <YES/NO>
13. How long have you been in practice (y)?
0–5, 6–10, 11–15, 16–20, 21–25, 26–30, 31–35, 36–40, >40
14. Choose the setting that best describes your practice:
Private, Private with an academic affiliation, Academic, Physician group, Nonacademic hospital, Other (please specify)
15. Choose the location that best describes where you practice:
Urban, Small town, Rural, Multiple locations, Other (please specify)
16. Select the option that best describes the payments your practice accepts:
Self-pay, private insurance, Medicare, Medicaid, All of the above, Salary with incentives, Salary without incentives (full-time), Salary without incentives (not full-time)
17. Are patient satisfaction tools used as a performance measure in your practice (eg, Hospital Consumer Assessment of Healthcare Providers and Systems survey OR Press Ganey Surveys)? <YES/NO>
18. Do patient satisfaction measures affect your financial reimbursement in any direct form (ie, salary income or incentives)? <YES/NO>
19. Have you ever felt institutional pressure to change your opiate prescription patterns?
Pressure to increase personal opiate prescribing practice, No pressure to change, Pressure to decrease personal opiate prescribing practice
20. Do you consult the prescription drug monitoring program, in your state, before prescribing?
Yes; No; My state has one, but I do not always consult it because it is not easily accessible; I am unaware whether my state has one; My state does not have one
21. Do you readily have access for patient referral to a pain management specialist? <YES/NO>
22. How would you describe the amount of formal instructions received in pain management and prescribing narcotics?
More than sufficient, Sufficient, Less than sufficient, None
23. Would you be interested in receiving more information regarding prescribing pain medication?
Very interested, Somewhat interested, Not interested
24. Does your preoperative care plan include any of the following? (verbal or written instructions)
Pain medication prescription information, Risk of pain medication addiction, Pain medication side effects, Secure storage of pain medication
25. Which of the following would you consider barriers or limitations to providing patients with education on narcotic medications and management? (check all that apply)
Patient already knows, Not enough time, Patient would not understand, Patient would not pay attention, Information will scare the patient, I am not aware of the risks, Rely on the pharmacist to review the risks, It is not my responsibility, It is not necessary for short-term prescriptions
26. Please rate the difficulty of this survey.
Very easy, Easy, Neither easy nor hard, Hard, Very hard

ASPS Member Demographics - Physician Prescribing Patterns: Plastic Surgeons

ASPS Practice Type	Overall Membership		PPP Survey Cohort		PPP Survey Responders		
Academic	12%	14%	11%	13%	16	6%	8%
Academic Practice (salaried with private practice)	2%		2%		5	2%	
Employed Physician	1%	1%	1%		4	2%	
Solo	48%	54%	49%	55%	151	57%	63%
Solo practice-shared facility	6%		5%		15	6%	
Large multi-specialty group practice (more than 20 physicians)	6%	30%	6%	30%	12	5%	27%
Large plastic surgery group practice (6 or more plastic surgeons)	3%		3%		9	3%	
Small plastic surgery group practice (2-5 plastic surgeons)	19%		19%		48	18%	
Medium multi-specialty group practice (6-20 physicians)	1%		1%		3	1%	
Military	1%	1%	1%	1%	2	1%	1%
	100%	100%	100%	100%	265	100%	98%

ASPS Practice Demographic	Overall Membership	PPP Survey Cohort	Survey Responders	
50% Reconstructive & 50% Cosmetic	27%	27%	88	32%
25% Reconstructive & 75% Cosmetic	26%	25%	78	28%
75% Reconstructive & 25% Cosmetic	23%	23%	40	15%
100% Cosmetic	16%	17%	51	19%
100% Reconstructive	9%	8%	18	7%
	100%	100%	275	100%

ASPS Gender	Overall Membership	PPP Survey Cohort	Survey Responders	
Female	17%	16%	66	22%
Male	83%	84%	232	78%
	100%	100%	298	100%

Fig. 1. ASPS member demographics—physician prescribing patterns: plastic surgeons.




Fig. 2. Response of plastic surgeons to what narcotic prescriptions were given for each procedure (breast augmentation, breast reduction, abdominoplasty).

Changes to Prescribing Patterns over the Last 5–10 Years

Changes in prescribing patterns and postoperative patient characteristics were as follows: overall 56.9% (N = 152) felt their narcotic prescribing frequency had decreased in the last 5–10 years, whereas 41.6% (N = 111)

described it as unchanged. Although the majority of plastic surgeons did not notice a change (63.7%; N = 170) in the frequency of narcotic prescription refill requests by patients, some felt there to be a minor increase (11.2%) or minor decrease (13.5%). Physicians felt that <25% of




Fig. 3. Response of plastic surgeons to what narcotic prescriptions were given most often for all procedures combined.




Fig. 4. Narcotic prescription dosage (mg) of oxycodone and hydrocodone with acetaminophen by procedure.

patients displayed drug seeking (97%; N = 259) or aggressive (99.3%; N = 265) behavior of any kind to receive added narcotics.

Prescribing Patterns and Patient Satisfaction Tools

Patient satisfaction tools (eg, Hospital Consumer Assessment of Healthcare Providers and Systems survey or Press Ganey Surveys) were used as a performance measure in 50.9% (N = 144) of practices. For the majority of plastic

surgeons, patient satisfaction measures did not affect financial reimbursement in any direct form (ie, salary income or incentives; 90.8%; N = 257). For those reporting use of patient satisfaction tools as a performance measure in their practice, there was no significant variation in use of nonnarcotic pain medication ($P = 0.467$) or narcotic prescriptions ($P = 0.417$). For those plastic surgeons in whom patient satisfaction measures affected their financial reimbursement, there was no significant variation in




Fig. 5. Narcotic prescription number of tablets dispensed of oxycodone and hydrocodone with acetaminophen by procedure.

use of nonnarcotic pain medication ($P = 0.267$) or narcotic prescriptions ($P = 0.573$).

Prescription Drug Monitoring Programs

The respondents (31.2%; $N = 88$) reported consulting their state’s prescription drug monitoring program (PDMP) before prescribing narcotics, whereas 36.2% ($N = 102$) do not. Plastics surgeons (22.3%; $N = 63$) did have a state PDMP but did not always consult it because they felt it was not easily accessible. Plastic surgeons (78.4%; $N = 221$) reported that they readily have access for patient referral to a pain management specialist. Only 17% ($N = 48$) of plastic surgeons described the amount of formal instructions they received in pain management and prescribing narcotics to be less than sufficient.

Pain Medication Patient Education

In regard to their preoperative care plan (verbal or written instructions), plastic surgeons provided the following: pain medication prescription information (88%; $N = 243$), risk of pain medication addiction (45.3%; $N = 124$), pain medication side effects (80.4%; $N = 221$), and secure storage of pain medication (36.8%; $N = 100$). The most commonly reported barrier or limitation to providing patients with education on narcotic medications and management was that the “patient won’t pay attention” (52.9%; $N = 146$); which was followed by “not enough time” (36.2%; $N = 100$) and “unnecessary for short term prescriptions” (34.1%; $N = 94$).

Prescribing Patterns and Years in Practice

Upon comparison of physician experience, there was no significant variation in use of nonnarcotic pain medication

($P = 0.672$) or narcotic prescriptions ($P = 0.213$) for those in practice <10 years versus those >10 years. In addition, most plastic surgeons felt no pressure to change personal opiate prescribing practice (76.3%; $N = 216$), although some felt pressure to decrease (21.9%; $N = 62$).

DISCUSSION

Opioid Use in Surgical Specialties

It is increasingly important for surgeons, emergency room and primary care providers, and their patients to understand the detrimental effects associated with opioid use. Nevertheless, prescription opioids remain an important analgesic in the treatment of acute postsurgical pain. The surgical specialties including general, orthopedic, plastic, cardiothoracic, vascular, colorectal, spinal, and neurologic prescribe opioid analgesics at a rate of 36.5% which accounts for 10% of the total opioid prescriptions in the United States.¹⁷ Despite their popularity in the treatment of postsurgical pain, opioid prescriptions written by surgeons often go unused. Surgeons prescribe 2–5 times more opioids than consumed, and 83% of patients claim to finish only half of the prescription.^{13,14} This may, however, be affected by patients reporting less than the actual amount consumed. In addition, 3 of 4 postoperative patients fail to lock stored narcotics or properly dispose of left over medications.¹⁸ Specifically, breast augmentation and breast reduction patients report an average of 12–18 unused pain pills postoperatively.¹⁹ However, the trend seen among surgical specialties from 2007 to 2012 indicates a decreasing pattern of opioid prescribing.¹⁷ This is

perhaps due to an increase in surgeons adopting the use of multimodal analgesia to treat postsurgical pain. In plastic surgery, multimodal analgesics have been shown to reduce opioid use and effectively treat postsurgical pain.^{20,21} Regular use of acetaminophen, ibuprofen, and celecoxib in plastic surgery patients without contraindications has been shown to provide sufficient pain control and reduce opioid requirements postoperatively.^{22–25}

Suggested Opioid Prescribing Guidelines for Surgeons

The Center for Disease Control issued guidelines for prescribing narcotics for chronic pain, but none exist for acute postoperative pain; however, surgeons operate on patients with chronic pain syndromes.²⁶ Chronic pain guidelines included the following: nonpharmacologic therapy and nonopioid pharmacologic combined with opioid pharmacologic therapy, establishing realistic goals for pain and function, discussing risks and realistic benefits of opioid therapy, avoiding extended-release/long-acting opioids, using the lowest effective dosage for 3–7 days, review of the patient's history of controlled substance prescriptions using state PDMP, and avoiding opioid pain medication and benzodiazepines concurrently when possible.

Although no opioid guidelines exist for plastic surgeons, the ACS support state PDMP, prescribing limits, the use of nonopioid alternatives, continuing medical education on opioid-specific training.²⁷ The American Pain Society, in collaboration with the American Society of Anesthesiologists, developed an evidence-based guideline on postoperative pain management. Key recommendations included multimodal technique (combining opioid and nonopioid medications) and local or regional anesthetic blocks.² Many states have recently instituted changes to opioid prescribing laws but they vary widely. For example, mandates in Louisiana for 2018 included limits to duration of narcotic treatment with required continuing education in controlled substances and addiction treatment.²⁸ Based on results of this ASPS survey, plastic surgeons seem to be appropriate in their prescribing patterns of narcotics with the majority giving lower dosages and enough pills to last no longer than a week with no refills. Their prescribing patterns were not affected by variation in procedure, practice setting or location, or number of years in practice. However, self-pay-only plastic surgeons all included a standard prescription as part of their perioperative discharge care package. Many plastic surgeons utilize nonnarcotic adjuncts, in addition to opioid, to manage postoperative pain which show an attempt for combination therapy pain management approach in line with ACS guidelines.

Use of State PDMP

One third of plastic surgeons consult their state's PDMP, whereas one third do not. Almost one fourth of plastics surgeons felt their state's drug monitoring was not easily accessible and thus hindered the consult; however, most plastic surgeons readily have access to a pain management specialist. Although PDMP are available in almost every state, studies show they did not allow or foster access by health care professionals. The U.S. Department of

Health and Human Services, in recent years, began funding the "Enhancing Access to Prescription Drug Monitoring Programs" project to aid in increasing physician access to services.²⁹ Although the procedures in this survey are cosmetic, and not subject to rules regarding Medicare reimbursement, plastic surgeons were answering overarching practice characteristic questions. Consulting PDMP is listed as one of the most relevant improvement activities related to Medicare reimbursements.³⁰ Therefore, ASPS education regarding Merit-Based Incentive Payment System could explain the increase in plastic surgeon reporting in comparison to the published surgeon national average consulting for PDMP.

Pain Medication and Patient Education

Although one third of plastic surgeons felt pain medication education was unnecessary for short-term pain prescriptions, those that did provide education mainly focused on the prescription and side effects. Only half talked to the patient about addiction and a third mentioned safe storage. Although <20% of plastic surgeons felt amount of formal instructions received in pain management and prescribing narcotics to be inadequate, it is possible that plastic surgeons need more education in providing opioid patient education; however, the most common reported barrier to education for plastic surgeons was the patient will not pay attention. Attempting to educate the day of the surgery has been shown to be less effective than during a preoperative appointment. This could be the reason why plastic surgeons felt patients do not pay attention.³¹ Although the survey revealed most plastic surgeon care plans included pain medication prescription information and pain medication side effects, less than half provided risk of pain medication addiction and secure storage of pain medication. The ASPS highlighted an article regarding tips on how plastic surgeons can manage opioid addiction risk. Suggested strategies for plastic surgeons included screening for risk factors of opioid use disorder, talking to patients about these risks in a nonjudgmental way, and informing the patient's primary care doctor about the possible increase in risk. In addition, referrals to an addiction specialist, before surgery, is recommended for patients with known or suspected substance use disorder. Neither the ASPS nor the ACS has specific guidelines regarding drug screening, but remaining alert to verbal and nonverbal clues will help guide physical examination to confirm suspicion.³¹ ASPS also promoted methods to reduce the need for narcotics such as anesthesia techniques and nonopioid pain management strategies.³²

Pain Management Recommendations by Procedure

In regards to plastic surgery patients, elective procedures were associated with higher rates of prolonged opioid use than trauma-related surgeries.³³ Muscle relaxers are recommended for abdominoplasties in conjunction with patient education regarding positioning and techniques to decrease strain to abdominal wall.³⁴ In addition, the use of epidural pain management reduced the need for opioids and shortened hospital stay for abdominoplasties.³⁵ On the same note, the use of self-adhering mesh

intraoperatively was associated with significantly less acute postoperative pain.³⁶ The use of nonnarcotic analgesics, such as NSAIDs, for breast augmentation was associated with significantly lower pain during the first 3 postoperative days, earlier recovery of bowel function and normal activities, without increase in bleeding risk.²¹

Limitations

Low response rate, 12% (298), is a limitation of this study. ASPs only allowed the survey to be sent random to 50% of their members. A PubMed search for “ASPS survey response” yielded 13 articles with an average reported survey response rate of 14.7%; thus, our ASPs member response rate of 12% is externally valid for the population sampled. Upon further investigation, one article looked at 1,607 different surveys from multiple academic journals and determined the average response rate of data collected from individuals to be 52.7% with an SD of 20.4.³⁷ As a whole, the low response rates of ASPs member surveys subjects results to nonresponse bias. Performing a nonresponse analysis, to compare survey respondents with nonrespondents, allows for assessment of potential bias in results.³⁸ Our study focused on board-certified plastic surgeons and did not look at physicians practicing outside the scope of their board practice. Future studies could survey the prescribing practices of a broad array of physicians, in relation to cosmetic procedures performed, through the aid of ACS or American Medical Association. Another limitation of this study could be insufficient power, despite 298 responses, to detect differences in narcotic and nonnarcotic patterns in relation to practice setting and physician characteristics. This affects the ability to generalize results to all plastic surgeons.

Two hundred and sixty-six of 298 respondents (89.3%) fully completed survey. Due to some respondents with partial survey completion, 32 of 298 respondents answered questions about narcotic and nonnarcotic prescribing patterns only. Therefore, this affected the number of responses regarding practice and physician characteristics. Due to the structure of the survey, it is not feasible to compare procedures to practice settings and physician characteristics. This is because after the randomization to a procedure, all respondents were directed to the same pages for the second half of the survey. The questions on this section were not specific to any procedure. In addition, the data collected through the survey were distributed to us for analysis directly from ASPs. This did not include practice characteristics separated by assigned procedure. This was not accounted for in data analysis. Geographical distribution of plastic surgeon respondents was not collected. This information could have added to the article, with the ability to report geographic tendencies with narcotic prescribing patterns.

CONCLUSIONS

Overall, plastic surgeons seem to be in compliance with proposed ACS opioid prescription guidelines: support state PDMP, prescribing limits, the use of nonopioid alternatives, continuing medical education on opioid-specific training. However, there remains a lack of evidence regarding appropriate opioid prescribing patterns

for plastic surgeons. This study brings awareness to the need for a large prospective study, which includes both plastic surgeon and patient responses, to develop plastic surgery prescribing guidelines.

Radbeh Torabi, MD

LSUHSC Plastic Surgery Resident
Department of Surgery
Section of Plastic & Reconstructive Surgery
Louisiana State University Health Sciences Center
1542 Tulane Ave, Room 748
New Orleans, LA 70112
E-mail: rtorab@lsuhsc.edu

Statement of Conformity: This study was conducted in accordance with the Declaration of Helsinki.

REFERENCES

1. Thiels CA, Anderson SS, Ubl DS, et al. Wide variation and overprescription of opioids after elective surgery. *Ann Surg.* 2017;266:564–573.
2. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. *J Pain.* 2016;17:131–157.
3. Hill MV, McMahon ML, Stucke RS, et al. Wide variation and excessive dosage of opioid prescriptions for common general surgical procedures. *Ann Surg.* 2017;265:709–714.
4. Janis JE, Joshi GP. Introduction to “current concepts in pain management in plastic surgery.” *Plast Reconstr Surg.* 2014;134(4 suppl 2):6S–7S.
5. Centers for Disease Control and Prevention. Opioid overdose. Available at <https://www.cdc.gov/drugoverdose/index.html>. Accessed April 16, 2018.
6. Daubresse M, Chang HY, Yu Y, et al. Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000–2010. *Med Care.* 2013;51:870–878.
7. Chang H-Y, Daubresse M, Kruszewski SP, et al. Prevalence and treatment of pain in emergency departments in the United States, 2000–2010. *Pharmacoepidemiol Drug Saf.* 2014;23:114.
8. Manchikanti L, Helm S, Fellows B, et al. Opioid epidemic in the United States. *Pain Physician.* 2012;15(3 suppl):ES9–E38.
9. Rudd RA, Seth P, David F, et al. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. *MMWR Morb Mortal Wkly Rep.* 2016;65:1445–1452.
10. Florence CS, Zhou C, Luo F, et al. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. *Med Care.* 2016;54:901–906.
11. Chen JH, Humphreys K, Shah NH, et al. Distribution of opioids by different types of medicare prescribers. *JAMA Intern Med.* 2016;176:259–261.
12. Maxwell JC. The prescription drug epidemic in the United States: a perfect storm. *Drug Alcohol Rev.* 2011;30:264–270.
13. Bartels K, Mayes LM, Dingmann C, et al. Opioid use and storage patterns by patients after hospital discharge following surgery. *PLoS One.* 2016;11:e0147972.
14. Gauger EM, Gauger EJ, Desai MJ, et al. Opioid use after upper extremity surgery. *J Hand Surg Am.* 2018;43:470–479.
15. Hooten WM, St Sauver JL, McGree ME, et al. Incidence and risk factors for progression from short-term to episodic or long-term opioid prescribing: a {population-based} study. *Mayo Clin Proc.* 2015;90:850–856.

16. American Society of Plastic Surgeons. 2017 Plastic Surgery Statistics. Available at <https://www.plasticsurgery.org/news/plastic-surgery-statistics>. Accessed May 2, 2018.
17. Levy B, Paulozzi L, Mack KA, et al. Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007–2012. *Am J Prev Med*. 2015;49:409–413.
18. Bicket MC, Long JJ, Pronovost PJ, et al. Prescription opioid analgesics commonly unused after surgery: a systematic review. *JAMA Surg*. 2017;152:1066–1071.
19. Hart AM, Broecker J, Kao L, et al. Opioid usage following outpatient breast surgery: are physicians part of the problem? *Plast Reconstr Surg*. 2018;142:611–620.
20. Lalonde D, Wong A. Local anesthetics: what's new in minimal pain injection and best evidence in pain control. *Plast Reconstr Surg*. 2014;134(4 suppl 2):40S–49S.
21. Low YH, Gan TJ. NMDA receptor antagonists, gabapentinoids, α -2 agonists, and dexamethasone and other non-opioid adjuvants: do they have a role in plastic surgery? *Plast Reconstr Surg*. 2014;134(4 suppl 2):69S–82S.
22. Simmons DL, Wagner D, Westover K. Nonsteroidal anti-inflammatory drugs, acetaminophen, cyclooxygenase 2, and fever. *Clin Infect Dis*. 2000;31(suppl 5):S211–S218.
23. Mitchell A, McCrear P, Inglis K, et al. A randomized, controlled trial comparing acetaminophen plus ibuprofen versus acetaminophen plus codeine plus caffeine (Tylenol 3) after outpatient breast surgery. *Ann Surg Oncol*. 2012;19:3792–3800.
24. Manassa EH, Hellmich S, Ronert M, et al. Pain management after lipoplasty: a study of 303 cases. *Plast Reconstr Surg*. 2005;115:1715–1721; discussion 1722.
25. Sun T, Sacan O, White PF, et al. Perioperative versus postoperative celecoxib on patient outcomes after major plastic surgery procedures. *Anesth Analg*. 2008;106:950–958, table of contents.
26. Marcusa DP, Mann RA, Cron DC, et al. Prescription opioid use among opioid-naïve women undergoing immediate breast reconstruction. *Plast Reconstr Surg*. 2017;140:1081–1090.
27. Saluja S, Selzer D, Meara JG, et al. The opioid epidemic: what can surgeons do about it? Available at <http://bulletin.facs.org/2017/07/the-opioid-epidemic-what-can-surgeons-do-about-it/#.WuJ9GJwbIU>. Published July 1, 2017. Accessed April 26, 2018.
28. Louisiana State Board of Medical Examiners. Opioid Prescribing Laws—Recent Changes. Available at <http://www.lsbme.la.gov/content/opioid-prescribing-laws-recent-changes>. Published January 4, 2018. Accessed January 13, 2018.
29. Wilsey B, Prasad H. Real-time access to prescription drug monitoring databases. *CMAJ*. 2012;184:1767–1768.
30. American Society of Plastic Surgeons. Participate in MIPS: Improvement Activities Performance Category. Available at <https://www.plasticsurgery.org/for-medical-professionals/health-policy/macra/participate-in-mips/mips-ia>. Accessed June 10, 2018.
31. Cone JD, Jr, Harrington MA, Kelley SS, et al. Drug abuse in plastic surgery patients: optimizing detection and minimizing complications. *Plast Reconstr Surg*. 2011;127:445–455.
32. Demsey D, Carr NJ, Clarke H, et al. Managing opioid addiction risk in plastic surgery during the perioperative period. *Plast Reconstr Surg*. 2017;140:613e–619e.
33. Johnson SP, Chung KC, Zhong L, et al. Risk of prolonged opioid use among opioid-naïve patients following common hand surgery procedures. *J Hand Surg Am*. 2016;41:947–957.e3.
34. Constantine FC, Matarasso A. Putting it all together: recommendations for improving pain management in body contouring. *Plast Reconstr Surg*. 2014;134(4 suppl 2):113S–119S.
35. Khansa I, Koogler A, Richards J, et al. Pain management in abdominal wall reconstruction. *Plast Reconstr Surg Glob Open*. 2017;5:e1400.
36. Khansa I, Janis JE. Abdominal wall reconstruction using retrorectus self-adhering mesh: a novel approach. *Plast Reconstr Surg Glob Open*. 2016;4:e1145.
37. Baruch Y, Holtom BC. Survey response rate levels and trends in organizational research. *Human Relations*. 2008;61:1139–1160.
38. Johnson TP, Wislar JS. Response rates and nonresponse errors in surveys. *JAMA*. 2012;307:1805–1806.